Buprenorphine, the primary take-home medication for individuals with moderate to severe opioid use disorder (OUD), faced potential disruptions during the COVID-19 pandemic. While previous studies have focused on short-term effects, our comprehensive analysis spans 33 months, leveraging California's prescription drug monitoring program (PDMP). Our findings reveal that the pandemic moderated the growth of prescriber numbers but had minimal impact on monthly patient volumes, prescriptions, or daily dosage.